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v Claudin-2 expression is increased in patients with 
immune checkpoint inhibitors colitis, which may 
contribute to epithelial barrier function and diarrhea.
v Expression is increased only in the intestinal crypts, in 
line with what is known about claudin-2 regulating 
barrier function predominantly in this area.
In the future, we would like to compare expression of 
other tight junction proteins as well. For example, claudin-
15 is another claudin channel which could contribute to 
increased water transport in the colon.
The Weber Lab has developed a novel class of claudin-2 
channel blockers and we intend to determine if the 
blockers can reduce paracellular water transport in colonic 
biopsies obtained from patients with anti-PD-1 colitis.
I would like to thank Dr. Christopher R. Weber, Dr. Le Shen, Dr. Ye Li, 
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throughout the summer. I am grateful for all their support in helping me 
work through this project. I would also like to thank Dr. Megan 
Mekinda, Dr. Eileen Dolan, and Michelle Domecki, the directors of the 
EYES on Cancer Program. This opportunity would not be possible 
without them. 
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Anti-PD-1/PD-L1 Therapy associated Colitis is associated 
with Upregulation of Tight Junction Claudin-2
Claudins are a family of tight junction proteins which are important in defining 
paracellular water flux in the gastrointestinal tract. This project aims to 
investigate if claudin-2 is upregulated in patients that experience colitis and 
diarrhea from anti-PD-1/PD-L1 immunotherapy. In epithelial cells, it has been 
shown that claudin-2 is upregulated in patients experiencing colitis and 
diarrhea [1]. Anti-PD-1/PD-L1 therapy is an immunotherapy used to treat 
cancer. Patients can experience severe colitis and diarrhea as a result of this 
medication. We performed immunohistochemical staining on 20 colon 
biopsies from patients experiencing colitis from anti-PD-1/PD-L1 therapy and 
compared them to aged matched controls. Our results showed that 
expression of claudin-2 in intestinal crypts was significantly higher in patients 
with anti-PD-1/PD-L1 colitis, which may contribute to increased paracellular 
water flux and diarrhea in these patients. 
Anti-Programed Cell Death-1 (PD-1) and Anti-Programed Cell Death-Ligand 1 (PD-
L1) are novel types of immune checkpoint inhibitors used to treat cancer. This 
immunotherapy uses monoclonal antibodies to block the checkpoint proteins on the 
T-cell and its partner protein [2]. By blocking these proteins, T-cells can recognize 
the cancer cells and destroy them. Although PD-1/PDL-1 therapy can be an 
effective anti-cancer therapy, this treatment has shown to cause gastrointestinal 
issues [3]. Severe colitis and diarrhea can occur [4]. These side effects can cause a 
patient to cease immunotherapy treatment and compromise their outcome [4]. 
Epithelial tight junctions are a complex of proteins that control the paracellular 
permeability of the cells that compose the epithelial barrier [4]. Claudin-2 is a 
transmembrane protein that forms cation-selective and water permeable 
paracellular channels [4]. Previous research has shown that claudin-2 is upregulated 
in compromised epithelial barriers caused by IBD and other types of colitis [4]. We 
are attempting to determine if Claudin-2 is also upregulated in patients who get 
colitis while taking anti-PD-1/PDL-1 medication. 
We hypothesize that Claudin-2 will be upregulated in 
colon samples taken from patients who are experiencing 









Immunohistochemical staining for claudin-2 was 
performed on formalin-fixed paraffin-embedded 
colonoscopic biopsies from 20 patients with anti-
PD-1/PD-L1 colitis and aged matched controls 
(representative images above).
Imagescope positive pixel count algorithm was 
used to quantify staining for claudin-2 within 
intestinal epithelial cells. Staining for claudin-2 
was significantly higher in crypt colonocytes of 
patients with anti-PD-1/PD-L1 colitis 
(P<0.05; students unpaired t test).
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